CN103857405B - 用于调节血清磷的治疗剂 - Google Patents

用于调节血清磷的治疗剂 Download PDF

Info

Publication number
CN103857405B
CN103857405B CN201280038112.5A CN201280038112A CN103857405B CN 103857405 B CN103857405 B CN 103857405B CN 201280038112 A CN201280038112 A CN 201280038112A CN 103857405 B CN103857405 B CN 103857405B
Authority
CN
China
Prior art keywords
hours
hemodialysis
seq
dialysis
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201280038112.5A
Other languages
English (en)
Chinese (zh)
Other versions
CN103857405A (zh
Inventor
F.凯林
G.贝尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kai Pharmaceuticals Inc
Original Assignee
Kai Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kai Pharmaceuticals Inc filed Critical Kai Pharmaceuticals Inc
Publication of CN103857405A publication Critical patent/CN103857405A/zh
Application granted granted Critical
Publication of CN103857405B publication Critical patent/CN103857405B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicinal Preparation (AREA)
CN201280038112.5A 2011-06-08 2012-06-08 用于调节血清磷的治疗剂 Active CN103857405B (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201161494874P 2011-06-08 2011-06-08
US61/494,874 2011-06-08
US61/494874 2011-06-08
PCT/US2012/041759 WO2012170955A1 (en) 2011-06-08 2012-06-08 Therapeutic agents for regulating serum phosphorus

Publications (2)

Publication Number Publication Date
CN103857405A CN103857405A (zh) 2014-06-11
CN103857405B true CN103857405B (zh) 2015-12-02

Family

ID=46321485

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280038112.5A Active CN103857405B (zh) 2011-06-08 2012-06-08 用于调节血清磷的治疗剂

Country Status (23)

Country Link
US (1) US8969299B2 (cg-RX-API-DMAC7.html)
EP (1) EP2717896B1 (cg-RX-API-DMAC7.html)
JP (1) JP5982473B2 (cg-RX-API-DMAC7.html)
KR (1) KR102057508B1 (cg-RX-API-DMAC7.html)
CN (1) CN103857405B (cg-RX-API-DMAC7.html)
AU (1) AU2012267470C1 (cg-RX-API-DMAC7.html)
BR (1) BR112013031539A2 (cg-RX-API-DMAC7.html)
CA (1) CA2837445C (cg-RX-API-DMAC7.html)
CY (1) CY1118430T1 (cg-RX-API-DMAC7.html)
DK (1) DK2717896T3 (cg-RX-API-DMAC7.html)
ES (1) ES2607986T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20161566T1 (cg-RX-API-DMAC7.html)
HU (1) HUE032087T2 (cg-RX-API-DMAC7.html)
LT (1) LT2717896T (cg-RX-API-DMAC7.html)
MX (1) MX337613B (cg-RX-API-DMAC7.html)
PL (1) PL2717896T3 (cg-RX-API-DMAC7.html)
PT (1) PT2717896T (cg-RX-API-DMAC7.html)
RS (1) RS55503B1 (cg-RX-API-DMAC7.html)
RU (1) RU2612912C2 (cg-RX-API-DMAC7.html)
SG (1) SG195290A1 (cg-RX-API-DMAC7.html)
SI (1) SI2717896T1 (cg-RX-API-DMAC7.html)
SM (2) SMT201700081T1 (cg-RX-API-DMAC7.html)
WO (1) WO2012170955A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2459208B1 (en) * 2009-07-29 2016-09-28 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels
PE20160549A1 (es) * 2013-06-28 2016-06-15 Amgen Inc Formulacion liquida estable de etelcalcetida (amg 416)
RU2686086C1 (ru) * 2018-05-17 2019-04-24 федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации Способ коррекции пресаркопении или саркопении у пациента с адекватным потреблением основных нутриентов, получающего лечение программным гемодиализом
WO2021115272A1 (zh) * 2019-12-09 2021-06-17 北京拓界生物医药科技有限公司 钙敏感受体激动剂化合物及其应用
KR20230066044A (ko) * 2020-09-10 2023-05-12 샨시 마이콧 테크놀로지 컴퍼니 리미티드 이중특이적 융합 폴리펩타이드 화합물

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067199A2 (en) * 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
WO2011014707A2 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5602116A (en) 1988-08-02 1997-02-11 Bone Care International, Inc. Method for treating and preventing secondary hyperparathyroidism
US5869473A (en) 1988-08-02 1999-02-09 Bone Care International, Inc. Method for treating and preventing hyperparathyroidism
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
US5246925A (en) 1989-03-09 1993-09-21 Wisconsin Alumni Research Foundation 19-nor-vitamin D compounds for use in treating hyperparathyroidism
AU9131091A (en) 1990-11-07 1992-06-11 Scripps Research Institute, The Peptides that inhibit platelet binding of adhesion molecules
US6011068A (en) 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6031003A (en) 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
WO1995006056A1 (en) 1993-08-20 1995-03-02 University Of Medicine & Dentistry Of New Jersey Bridged polycationic polymer-oligonucleotide conjugates and methods for preparing same
CA2145214A1 (en) 1995-02-28 1996-08-29 Rick E. Preddie Agents for pre-symptomatic diagnosis, prevention and cure huntington's disease (hd) in humans
US5688489A (en) 1995-09-15 1997-11-18 Resolution Pharmaceuticals, Inc. Non-receptor mediated imaging agents
US5895368A (en) * 1996-09-23 1999-04-20 Medisystems Technology Corporation Blood set priming method and apparatus
US6165977A (en) 1996-10-18 2000-12-26 Board Of Trustees Of The Leland Stanford Junior University Isozyme-specific activators of protein kinase C methods and compositions
US6258774B1 (en) 1998-03-19 2001-07-10 University Of Medicine And Dentistry Of New Jersey Carrier for in vivo delivery of a therapeutic agent
JP2000336099A (ja) 1999-05-27 2000-12-05 Sekisui Chem Co Ltd ペプチド及びc型肝炎抗体検出用試薬
US6274169B1 (en) 1999-08-02 2001-08-14 Abbott Laboratories Low oxygen content compostions of 1α, 25-dihydroxycholecalciferol
US6051567A (en) 1999-08-02 2000-04-18 Abbott Laboratories Low oxygen content compositions of 1α, 25-dihydroxycholecalciferol
JP2004504295A (ja) 2000-07-18 2004-02-12 ボーン ケア インターナショナル インコーポレイテッド 安定化1α−ヒドロキシビタミンD
US20080249016A1 (en) 2000-09-18 2008-10-09 Sanos Bioscience A/S Use of GLP-2 in a combination treatment for bone-related disorders
US20020168354A1 (en) 2000-11-10 2002-11-14 Daria Mochly-Rosen psiepsilonRack peptide composition and method for protection against tissue damage due to ischemia
CA2434643C (en) 2001-01-18 2013-10-29 The Board Of Trustees Of The Leland Stanford Junior University Peptides for activation and inhibition of.delta.pkc
AU2002240312A1 (en) 2001-02-08 2002-08-19 Pankaj Paranjp Enhanced oral and transcompartmental delivery of therapeutic or diagnostic agents using polymer conjugates
US20030036627A1 (en) 2001-02-16 2003-02-20 Montelaro Ronald C. Virus derived antimicrobial peptides
US7253146B2 (en) 2001-02-23 2007-08-07 Polyphor Ltd Template-fixed peptidomimetics with antimicrobial activity
JP2005287302A (ja) 2002-04-03 2005-10-20 Haruhiko Fujiwara ポリペプチドの架橋方法
AU2003299496A1 (en) 2002-05-14 2004-05-25 Bristol-Myers Squibb Company Polynucleotide encoding novel human g-protein coupled receptors, and splice variants thereof
WO2004093821A2 (en) 2003-04-22 2004-11-04 Hawaii Biotech, Inc. Treatment of anthrax infection using inhibitors of lethal factor protease activity
CA2543072A1 (en) 2003-11-05 2005-06-02 Pevion Biotech Ltd. Compositions comprising melittin-derived peptides and methods for the potentiation of immune responses against target antigens
US20050187156A1 (en) 2003-12-11 2005-08-25 Daria Mochly-Rosen Isozyme-specific antagonists of protein kinase C
US7939634B2 (en) 2004-01-27 2011-05-10 Compugen Ltd. Polynucleotides encoding polypeptides and methods using same
US7265092B2 (en) 2004-09-30 2007-09-04 Kai Pharmaceuticals, Inc. Pharmaceutical formulation
ITME20040015A1 (it) * 2004-12-07 2005-03-07 Vincenzo Savica Chewing gum, caramelle gommose, pastiglie, compresse a lento rilascio di chelanti fosfato e/o fosforo salivare e capsule a lento rilascio di chelanti fosfato e/o fosforo a livello gastroenterico.
US20070066514A1 (en) 2005-08-30 2007-03-22 Acologix, Inc. Regulation of mineral and skeletal metabolism
WO2007038172A2 (en) 2005-09-23 2007-04-05 Nitto Denko Corporation Guanidinium carriers
US8067532B2 (en) 2007-01-19 2011-11-29 Kai Pharmaceuticals, Inc. Modifications of peptide compositions to increase stability and delivery efficiency
AU2008308679B2 (en) 2007-10-02 2015-01-29 Marina Biotech, Inc. Lipopeptides for delivery of nucleic acids
EP2229473A4 (en) 2007-12-07 2011-02-02 Steven A Goldstein IDENTIFICATION OF TOXIN LIGANDS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008067199A2 (en) * 2006-11-16 2008-06-05 Kai Pharmaceuticals, Inc. Polycationic calcium modulator peptides for the treatment of hyperparathyroidism and hypercalcemic disorders
WO2011014707A2 (en) * 2009-07-29 2011-02-03 Kai Pharmaceuticals, Inc. Therapeutic agents for reducing parathyroid hormone levels

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Implementation of ‘K/DOQI Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease" after the introduction of cinacalcet in a population of patients on chronic haemodialysis;Maria Dolores Arenas et al.;《NEPHROLOGY DIALYSIS TRANSPLANTATION》;20070630;第22卷(第6期);1639-1644 *

Also Published As

Publication number Publication date
MX2013014249A (es) 2014-01-24
EP2717896B1 (en) 2016-08-24
CA2837445A1 (en) 2012-12-13
KR102057508B1 (ko) 2019-12-19
WO2012170955A1 (en) 2012-12-13
SI2717896T1 (sl) 2017-04-26
JP2014522414A (ja) 2014-09-04
LT2717896T (lt) 2017-02-27
SG195290A1 (en) 2013-12-30
MX337613B (es) 2016-03-10
PT2717896T (pt) 2016-12-23
AU2012267470C1 (en) 2017-09-21
AU2012267470B2 (en) 2017-06-15
EP2717896A1 (en) 2014-04-16
US8969299B2 (en) 2015-03-03
PL2717896T3 (pl) 2017-05-31
KR20140035456A (ko) 2014-03-21
BR112013031539A2 (pt) 2019-07-30
ES2607986T3 (es) 2017-04-05
HUE032087T2 (en) 2017-08-28
CY1118430T1 (el) 2017-06-28
RU2013157928A (ru) 2015-07-20
SMT201700081B (it) 2017-03-08
CA2837445C (en) 2022-10-04
CN103857405A (zh) 2014-06-11
HRP20161566T1 (hr) 2017-02-24
RS55503B1 (sr) 2017-05-31
US20130150301A1 (en) 2013-06-13
DK2717896T3 (en) 2016-12-19
SMT201700081T1 (it) 2017-03-08
RU2612912C2 (ru) 2017-03-13
JP5982473B2 (ja) 2016-08-31

Similar Documents

Publication Publication Date Title
US20250163103A1 (en) Therapeutic agents for reducing parathyroid hormone levels
TW202317604A (zh) 用於治療遺傳性血鐵沉積症之鐵調素模擬物
EP2717896B1 (en) Therapeutic agents for regulating serum phosphorus
AU2012267470A1 (en) Therapeutic agents for regulating serum phosphorus
JP7440132B2 (ja) 二重特異性融合ポリペプチド化合物
HK1196939B (en) Therapeutic agents for regulating serum phosphorus
CN117480176A (zh) 用于治疗遗传性血色病的铁调素模拟物
HK40072695B (en) Bispecific fusion polypeptide compound
HK40072695A (en) Bispecific fusion polypeptide compound

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant